APA (7th ed.) Citation

MS, J., JAE, P., N, F., NV, J., JR, H., ABB, I., . . . AKM, D. (2025). Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab. Clinical genitourinary cancer, 23(6), 102450. https://doi.org/10.1016/j.clgc.2025.102450

Chicago Style (17th ed.) Citation

MS, Jespersen, et al. "Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab." Clinical Genitourinary Cancer 23, no. 6 (2025): 102450. https://doi.org/10.1016/j.clgc.2025.102450.

MLA (9th ed.) Citation

MS, Jespersen, et al. "Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab." Clinical Genitourinary Cancer, vol. 23, no. 6, 2025, p. 102450, https://doi.org/10.1016/j.clgc.2025.102450.